Just released: our top 3 small-cap stocks to consider buying in December [PREMIUM PICKS]
Premium content from Motley Fool Hidden Winners UK
Our monthly Best Buys Now are designed to highlight our teamâs three favourite, most timely Buys from our growing list of small-cap recommendations, to help Fools build out their stock portfolios.
“Best Buys Now” Pick #1:
Tristel (LSE:TSTL)
Why we like it: âTristel (LSE: TSTL), is an innovative healthcare firm based in Cambridge. Its unique disinfectant products are high-margin, quick to deploy, and cost effective. The recent regulatory approval for its DUO ultrasound product in the US has seen it enter the worldâs largest ultrasound market â a significant opportunity long in the making. Encouragingly, it has already onboarded a growing number of hospital customers in the US.âThe company has also received regulatory approval in Canada for a high-level disinfectant for ultrasound probes, bolstering its North American growth prospects. We hope that Tristel can build on its recent progress and eventually take a position as global market leader. The opportunity for investors in the firm is that Tristelâs top-line growth accelerates and its profitability increases as royalties from the product rollout in North America come on stream.â
Why we like it now: Tristelâs partnered with a US partner, Parker Laboratories, to manufacture and sell its Tristel ULT high level disinfection product to US hospitals. Tristel will receive a royalty on sales of 24%, which will produce lower revenues than selling direct, but with no direct costs meaning sales largely translate into operating profit. So far, commercial progress has been limited, with royalty income in the US of just £108k in the latest fiscal year partly due to âcomplex purchasing pathwaysâ. However, the opportunity could be huge, given Tristel estimates an addressable market of $150m. Tristel says it has engaged with roughly 200 health systems with adoption âsteadily buildingâ as Parker leverages its nationwide salesforce and distribution network. With Tristel also receiving FDA clearance earlier this year for a high-level disinfectant for ophthalmic instruments â Tristel OPH. The total market opportunity for Tristel OPH is around $32m per year. Tristelâs confident North America will make a âmeaningful contribution to Group revenues over the coming yearsâ. While investors await news of further progress in North America, the offers a trailing yield of 3.9% supported by strong cash generation.
“Best Buys Now” Pick #2:
Redacted
Want All 3 âBest Buys Nowâ Picks? Enter Your Email Address!
I would like to receive emails from you about product information and offers from The Fool and its business partners. Each of these emails will provide a link to unsubscribe from future emails. More information about how The Fool collects, stores, and handles personal data is available in its Privacy Statement.
The post Just released: our top 3 small-cap stocks to consider buying in December [PREMIUM PICKS] appeared first on The Motley Fool UK.
Should you invest £1,000 in Tristel Plc right now?
When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.
And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Tristel Plc made the list?
More reading
- Is the unloved Aston Martin share price about to do a Rolls-Royce?
- How much do you need in a Stocks and Shares ISA to raise 1.7 children?
- A Santa rally could take the FTSE 100 to 10,000 and beyond!
- 2 investment trusts from the FTSE 250 worth digging into for passive income
- The Games Workshop share price is up 38% in a year. Is there any value left?
The Motley Fool UK has recommended Tristel plc.
